DNA threading agents: Effect of sidechain bulk on DNA binding and cytotoxicity of 9-anilinoacridine-4-carboxamides

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 15, 1996, Pages 1831-1836

  Searcey, Mark ^a   Martin, P Noel ^a   Howarth, Nicola M ^a   Madden, Bernie ^a   Wakelin, Laurence P G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PKA; SPECTROPHOTOMETRY; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

EID: 0030572494     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00325-3     Document Type: Article

References (20)

1. 1) Searle M. S.; Hall, J. G.; Denny, W. A.; Wakelin, L. P. G. Biochemistry, 1988, 27, 4340
2. 2) a) Wakelin, L. P. G.; Atwell, G. J.; Rewcastle, G. W.; Denny, W. A. J. Med. Chem, 1987, 30, 855
3. b) Wakelin L. P. G.; Chetcuti, P.; Denny, W. A. J. Med Chem, 1990, 33, 2039
4. c) Wakelin, L. P. G.; Denny W. A. Molecular Basis of Specificity in Nucleic Acid Drug Interactions, Pullman B. and Jortner J. Eds.; Kluwer Academic Publishers: Netherlands, 1990; pp191-206
5. 3) a) Agbandje, M.; Jenkins, T. C.; McKenna, R.; Reszka, A. P.; Neidle S. J. Med Chem., 1992, 35, 1418
6. b) Zhao, M; Janda, L.; Nguyen, J.; Strekowski, L.; Wilson, W. D. Biopolymers, 1994, 34, 61.
7. c) Tanious, F. A., Yen, S-F, Wilson W.D. Biochemistry, 1991, 30, 1813
8. 4) a) Fok, J.; Waring, M. J. Mol. Pharmacol., 1972, 8, 65
9. b) Li, L. H.; Kuentzel, S. L.; Murch, L. I.; Pschigoda, L. M.; Krueger, W. C. Cancer Res., 1979, 39, 4816
10. c) Ennis, H. L. Antimicrob. Agents Chemother., 1981, 19, 657-665
11. 5) Rewcastle, G.W.; Denny, W. A. Synthesis, 1985, 220
12. 13C NMR spectroscopy and microanalysis.
13. 7) Hudson, B.D., Kuroda, R., Denny, W. A., Neidle, S. J. Biomol. Struct. Dyn. 1987, 5, 145
14. 8) a)Norden, B.; Kubista, M.; Kurucsev, T. Quart. Rev. Biophysics 1992, 25, 51
15. b)McFadyen, W. D.; Sotirellis, N.; Denny, W. A.; Wakelin, L. P. G. Biochim. Biophys. Acta. 1990, 1048, 50
16. 9)UV/visible spectra were obtained using a Hewlett Packard Vectra 286/12 at 20°C with 10mm path length length cuvettes. Concentrations of drug (10-20μM to minimise aggregation) were added to SHE buffer (I = 0.1) or to DNA (0.5mM) in SHE buffer (I = 0.1) or to 10 mM SDS in 0.1 SHE buffer. The spectra were run between 300 and 600 nm.
17. 10)Denny, W.A, Wakelin, L.P.G; Cancer Res, 1986, 46, 1717
18. 11) These experiments were carried out as per the procedures outlined earlier for pH 7.0, except that in place of 0.1 SHE at pH 7.0, 0.1 sodium acetate buffer was used
19. 50 is the concentration of drug required for 50% growth inhibition.
20. 13)Denny, W.A.; Roos, I. A. G.; Wakelin, L. P. G. Anti-Cancer Drug. Des. 1986, 1, 141-147